Clinical evidence and mechanistic basis for vildagliptin's action when added to metformin

Diabetes, Obesity and Metabolism

Volumn 13, Issue 3, 2011, Pages 193-203

  Ahren B ^a   Foley, J E ^b   Bosi, E ^c  

^a LUND UNIVERSITY   (Sweden)

^b NOVARTIS PHARMA AG   (Switzerland)

^c VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

Antidiabetic drug; Beta cell; Diabetes mellitus; Dipeptidyl peptidase 4; DPP 4 inhibitor; GIP; GLP 1; HbA1c; Insulin resistance; Islet function; Type 2 diabetes

Indexed keywords

ALOGLIPTIN; DIPEPTIDYL PEPTIDASE IV; EXENDIN 4; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A1C; LINAGLIPTIN; LIRAGLUTIDE; METFORMIN; PIOGLITAZONE; SAXAGLIPTIN; SITAGLIPTIN; VILDAGLIPTIN;

ADD ON THERAPY; BINDING AFFINITY; CLINICAL TRIAL (TOPIC); DISSOCIATION; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; ENZYME ACTIVE SITE; ENZYME INHIBITION; EVENING DOSAGE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; MEDLINE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET ALPHA CELL; PANCREAS ISLET BETA CELL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

EID: 78851471216     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2010.01321.x     Document Type: Review

References (76)

1. Villhauer EB, Brinkman JA, Naderi GB et al. 1-[[(3-hydroxy-1-adamantyl) amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J Med Chem 2003; 46: 2774-2789.
2. Ahren B, Foley JE. The islet enhancer vildagliptin: mechanisms of improved glucose metabolism. Int J Clin Pract Suppl 2008; 159: 8-14.
3. He YL, Serra D, Wang Y et al. Pharmacokinetics and pharmacodynamics of vildagliptin in patients with type 2 diabetes mellitus. Clin Pharmacokinet 2007; 46: 577-588.
4. Azuma K, Radikova Z, Mancino J et al. Measurements of islet function and glucose metabolism with the DPP-4 inhibitor vildagliptin in patients with type 2 diabetes. J Clin Endocrinol Metab 2007; 93: 459-464.
5. Ahren B. Vildagliptin: novel pharmacological approach to treat type 2 diabetes. Therapy 2008; 5: 79-90.
6. Drucker DJ. Biological actions and therapeutic potential of the glucagon-like peptides. Gastroenterology 2002; 122: 531-544.
7. Dejager S, Razac S, Foley JE, Schweizer A. Vildagliptin in drug-naive patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study. Horm Metab Res 2007; 39: 218-223.
8. Pi-Sunyer FX, Schweizer A, Mills D, Dejager S. Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetes. Diabetes Res Clin Pract 2007; 76: 132-138.
9. Schweizer A, Couturier A, Foley JE, Dejager S. Comparison between vildagliptin and metformin to sustain reductions in HbA1c over one year in drug-naÏve patients with type 2 diabetes. Diabet Med 2007; 24: 955-961.
10. Schweizer A, Dejager S, Bosi E. Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Obes Metab 2009; 11: 804-812.
11. Pan C, Yang W, Barona JP et al. Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24-week, double-blind, randomized trial. Diabet Med 2008; 25: 435-441.
12. Ahren B, Gomis R, Standl E, Mills D, Schweizer A. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care 2004; 27: 2874-2880.
13. Bosi E, Camisasca RP, Collober C, Rochotte E, Garber AJ. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care 2007; 30: 890-893.
14. Blonde L, Dagogo-Jack S, Banerji MA et al. Comparison of vildagliptin and thiazolidinedione as add-on therapy in patients inadequately controlled with metformin: results of the GALIANT trial-a primary care, type 2 diabetes study. Diabetes Obes Metab 2009; 11: 978-986.
15. Bolli G, Dotta F, Colin L, Minic B, Goodman M. Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Obes Metab 2009; 11: 589-595.
16. Bolli G, Dotta F, Rochotte E, Cohen SE. Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study. Diabetes Obes Metab 2008; 10: 82-90.
17. Bosi E, Dotta F, Jia Y, Goodman M. Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus. Diabetes Obes Metab 2009; 11: 506-515.
18. Ferrannini E, Fonseca V, Zinman B et al. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes Metab 2009; 11: 157-166.
19. Garber AJ, Schweizer A, Baron MA, Rochotte E, Dejager S. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study. Diabetes Obes Metab 2007; 9: 166-174.
20. Rosenstock J, Baron MA, Camisasca RP, Cressier F, Couturier A, Dejager S. Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared to component monotherapy in patients with type 2 diabetes. Diabetes Obes Metab 2007; 9: 175-185.
21. Garber AJ, Foley JE, Banerji MA et al. Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea. Diabetes Obes Metab 2008; 10: 1047-1056.
22. Fonseca V, Schweizer A, Albrecht D, Baron MA, Chang I, Dejager S. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia 2007; 50: 1148-1155.
23. Fonseca V, Baron M, Shao Q, Dejager S. Sustained efficacy and reduced hypoglycemia during one year of treatment with vildagliptin added to insulin in patients with type 2 diabetes mellitus. Horm Metab Res 2008; 40: 427-430.
24. Ahren B, Pacini G, Foley JE, Schweizer A. Improved meal-related β-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. Diabetes Care 2005; 28: 1936-1940.
25. Hollander PA, Schwartz SL, Gatlin MR et al. Importance of early insulin secretion: comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes. Diabetes Care 2001; 24: 983-988.
26. Balas B, Baig MR, Watson C et al. The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single dose administration in type 2 diabetic patients. J Clin Endocrinol Metab 2007; 92: 1249-1255.
27. Holst JJ, Deacon CF. Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors. Diabetologia 2005; 48: 612-615.
28. Nauck MA, El-Ouaghlidi A. The therapeutic actions of DPP-IV inhibition are not mediated by glucagon-like peptide-1. Diabetologia 2005; 48: 608-611.
29. Mari A, Sallas WM, He YL et al. Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed β-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab 2005; 90: 4888-4894.
30. Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 1993; 91: 301-307.
31. Vilsboll T, Krarup T, Madsbad S, Holst JJ. Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients. Diabetologia 2002; 45: 1111-1119.
32. Meier JJ, Hucking K, Holst JJ, Deacon CF, Schmiegel WH, Nauck MA. Reduced insulinotropic effect of gastric inhibitory polypeptide in first-degree relatives of patients with type 2 diabetes. Diabetes 2001; 50: 2497-2504.
33. Meier JJ, Gallwitz B, Siepmann N et al. Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia. Diabetologia 2003; 46: 798-801.
34. Chia CW, Carlson OD, Kim W et al. Exogenous glucose-dependent insulinotropic polypeptide worsens post prandial hyperglycemia in type 2 diabetes. Diabetes 2009; 58: 1342-1349.
35. Mayerson AB, Hundal RS, Dufour S et al. The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes 2002; 51: 797-802.
36. Boschmann M, Engeli S, Dobberstein K et al. Dipeptidyl-peptidase-IV inhibition augments postprandial lipid mobilization and oxidation in type 2 diabetic patients. J Clin Endocrinol Metab 2009; 94: 846-852.
37. Matikainen N, Mänttäri S, Schweizer A et al. Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes. Diabetologia 2006; 49: 2049-2057.
38. Sancho V, Trigo MV, Martin-Duce A et al. Effect of GLP-1 on D-glucose transport, lipolysis and lipogenesis in adipocytes of obese subjects. Int J Mol Med 2006; 17: 1133-1137.
39. Valverde I, Villanueva-Penacarrillo ML, Malaisse WJ. Pancreatic and extrapancreatic effects of GLP-1. Diabetes Metab 2002; 28: 3S85-3S89.
40. Villanueva-Penacarrillo ML, Marquez L, Gonzalez N, Díaz-Miguel M, Valverde I. Effect of GLP-1 on lipid metabolism in human adipocytes. Horm Metab Res 2001; 33: 73-77.
41. Hauner H, Glatting G, Kaminska D, Pfeiffer EF. Effects of gastric inhibitory polypeptide on glucose and lipid metabolism of isolated rat adipocytes. Ann Nutr Metab 1988; 32: 282-288.
42. Yip RGC, Wolfe MM. GIP biology and fat metabolism. Life Sci 2000; 66: 91-103.
43. Ahren B, Foley JE, Ferrannini E et al. Changes in prandial glucagon levels after 2-year treatment with vildagliptin or glimepiride in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy. Diabetes Care 2010; 33: 730-732.
44. Filozof C, Gautier J-F. A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study. Diabet Med 2010; 27: 318-326.
45. Matthews DR, Dejager S, Ahren B et al. Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study. Diabetes Obes Metab 2010; 12: 780-789.
46. Mari A, Scherbaum WA, Nilsson PM et al. Characterization of the influence of vildagliptin on model-assessed {beta}-cell function in patients with type 2 diabetes and mild hyperglycemia. J Clin Endocrinol Metab 2008; 93: 103-109.
47. Ahren B, Schweizer A, Dejager S et al. Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes. J Clin Endocrinol Metab 2009; 94: 1236-1243.
48. Hu S, Wang S, Dunning BE. Glucose-dependent and glucose-sensitizing insulinotropic effect of nateglinide: comparison to sulfonylureas and repaglinide. Int J Exp Diabetes Res 2001; 2: 63-72.
49. Landstedt-Hallin L, Lins PE, Adamson U. Oral glibenclamide suppresses glucagon secretion during insulin-induced hypoglycemia in patients with type 2 diabetes. J Clin Endocrinol Metab 1999; 84: 3140-3145.
50. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
51. Filozof C, Schwartz S, Foley JE. Effect of vildagliptin as add-on therapy to a low-dose metformin. World J Diabetes 2010; 1: 19-26.
52. Potashman MH, Duggan ME. Covalent modifiers: an orthogonal approach to drug design. J Med Chem 2009; 52: 1231-1246.
53. Metzler WJ, Yanchunas J, Weigelt C et al. Involvement of DPP-IV catalytic residues in enzyme-saxagliptin complex formation. Protein Sci 2008; 17: 240-250.
54. Svendsen PF, Nilas L, Madsbad S, Holst JJ. Incretin hormone secretion in women with polycystic ovary syndrome: roles of obesity, insulin sensitivity, and treatment with metformin. Metabolism 2009; 58: 586-593.
55. Migoya EM, Miller J, Larson P et al. Sitagliptin, a selective DPP-4 inhibitor, and metformin have complementary effects to increase active GLP-1 concentration. Diabetes 2007; 56(Suppl. 1): A74 (Abstract 286-OR).
56. Dunning BE, Ligueros-Saylan M, D'Alessio DA et al. Differential effects of DPP-4 inhibition on incretin hormone levels in drug-naive and metformin-treated patients with type 2 diabetes. Diabetologia 2006; 49(Suppl. 1): 110-111.
57. Yasuda N, Inoue T, Nagakura T et al. Enhanced secretion of glucagon-like peptide 1 by biguanide compounds. Biochem Biophys Res Commun 2002; 298: 779-784.
58. Green BD, Irwin N, Duffy NA, Gault VA, O'Harte FP, Flatt PR. Inhibition of dipeptidyl peptidase-IV activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1. Eur J Pharmacol 2006; 547: 192-199.
59. Lindsay JR, Duffy NA, McKillop AM et al. Inhibition of dipeptidyl peptidase IV activity by oral metformin in Type 2 diabetes. Diabet Med 2005; 22: 654-657.
60. Duffy NA, Green BD, Irwin N et al. Effects of antidiabetic drugs on dipeptidyl peptidase IV activity: nateglinide is an inhibitor of DPP IV and augments the antidiabetic activity of glucagon-like peptide-1. Eur J Pharmacol 2007; 568: 278-286.
61. Foley JE, Ligueros-Saylan M, Watson CA et al. Differential effects of vildagliptin on islet function in patients with type 2 diabetes receiving no additional agent or concomitant metformin. Diabetologia 2006; 49(Suppl. 1): 397-398.
62. Scheen AJ. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes Obes Metab 2010; 12: 648-658.
63. Nauck MA, Ellis GC, Fleck PR, Wilson CA, Mekki Q. Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study. Int J Clin Pract 2009; 63: 46-55.
64. Uhlig-Laske B, Ring A, Graefe-Mody U et al. Linagliptin, a potent and selective DPP-4 inhibitor, is safe and efficacious in patients with inadequately controlled type 2 diabetes despite metformin therapy. Diabetes 2009; 58(Suppl. 1): A143 (Abstract 535-P).
65. Taskinen M-R, Rosenstock J, Tamminen I et al. Efficacy and safety of linagliptin in type 2 diabetes inadequately controlled on metformin monotherapy. Diabetes 2010; 59(Suppl. 1): A158 (Abstract 579-P).
66. Scheen AJ, Charpentier G, Ostgren CJ, Hellqvist A, Gause-Nilsson I. Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus. Diabetes Metab Res Rev 2010; 26: 540-549.
67. DeFronzo RA, Hissa MN, Garber AJ et al. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care 2009; 32: 1649-1655.
68. Goke B, Gallwitz B, Eriksson J, Hellqvist A, Gause-Nilsson I. Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial. Int J Clin Pract 2010; 64: 1619-1631.
69. Charbonnel B, Karasik A, Liu J, Wu M, Meininger G. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006 29: 2638-2643.
70. Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2007; 9: 194-205.
71. Raz I, Chen Y, Wu M et al. Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes. Curr Med Res Opin 2008; 24: 537-550.
72. Scott R, Loeys T, Davies MJ, Engel SS. Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes. Diabetes Obes Metab 2008; 10: 959-969.
73. Bergenstal R, Forti A, Chiasson JL et al. Once weekly taspoglutide, a human GLP-1 analog, is superior to sitagliptin in improving glycemic control and weight loss in patients with type 2 diabetes (T2D): Results from the T-emerge Trial. Diabetes 2010; 59(Suppl. 1): A16 (Abstract 58-OR).
74. Pratley RE, Nauck M, Bailey T et al. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet 2010; 375: 1447-1456.
75. Bergenstal RM, Wysham C, Macconell L et al. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet 2010; 376: 431-439.
76. Gerich J. DPP-4 inhibitors: What may be the clinical differentiators? Diabetes Res Clin Pract 2010; 90: 131-140.